A bacteria-based cancer therapy has been engineered that eradicates tumors in immunocompromised mice—no immune cells required.

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

In addition to cell line development, CHO Plus partnered to scale up Avid Bioservices' mAb production to meet industrial scale requirements.

In this GEN webinar, eight experts discuss collaborative strategies and technological innovations that are shaping the future of malaria drug development.